Menu
Locate Bio
Locate is based in MediCity and has developed a family of unique, thermally-activated, injectable scaffolds that solidify within the body and can be used to support tissue growth before degrading away.
Regenerative medicine
School of Pharmacy
Profile
The TAOSTM (Targeted, Orchestrated Signalling) technology is a world first in tissue repair and enables the precision focus of therapeutic signals from small molecule or biological actives at the site of repair. TAOSTM has many potential application sites across the body.
Pipeline technology includes RPMax, a thermo-reversible matrix, and IntraStem, a new delivery system for cells; technologies that can meet industry recognised needs to advance cell therapy markets such as transfection, genome editing and induced pluripotent stem cells.
News and press releases
Our mission is to provide next generation products, both as tools and treatments, that will allow regenerative medicine to realise its potential. Our proprietary TAOS and Intrastem technologies give Locate a unique opportunity to develop and enable the next generation of cellular and gene therapies.
Robin Quirk
Chief Operating Officer
@locatebio on Twitter
@LocateBio will be attending #BioEquity in Barcelona on 20-21 May and #BIO2019 in Philadelphia on 3-6 June. CEO Nick Staples will be available for investor and partnering meetings.
@LocateBio receives £2million of new investment to advance #IntraStem its non-viral gene therapy technology and #TAOS cell delivery platform, and expand its in-house cell and gene therapy pipeline. £1.8million was a direct investment from @MerciaTech and £0.2m from MEIF.
@LocateBio CEO Nick Staples will be attending Cell and Gene Therapy #MeetingontheMed on 23-25th April
#MidlandsEngine #MEIF reaches first milestone - £25m of investment supported #Midlands wide including Medilink EM members @LocateBio! - @midsengine #EastMidlands #WestMidlands -
£250m investment fund reaches first milestone
The £250m Midlands Engine Investment Fund has reached its first milestone after supporting investment of £25m in the region’s businesses.
www.insidermedia.com
@Locatebio notes that the #FDA will promote the continued development of new cell and gene therapies, by adding as many as 50 additional reviewers to its staff, leveraging expedited pathways and issuing new guidance. Positive news as @LocateBio expands into gene therapy.
@LocateBio notes #FDA comments that by 2020, it expects upwards of 200 INDs for cell and gene therapies each year, adding to the 800 active INDs for such products already filed. By 2025, they expect to be approving between 10 and 20 cell and gene therapy products annually.
@LocateBio granted key patents in US and Europe for #IntraStem, a next gen cell penetrating peptide-based intracellular delivery (#transfection) system that overcomes the limitations of gene therapy vectors, with greater versatility, safety & lower COGs.
Locate Bio is granted key US and EU patents for its IntraStem™ non-viral, next generation gene delivery technology - Locate Bio
IntraStem is a cell penetrating peptide (CPP) based intracellular delivery system designed to overcome the limitations of current gene therapy vectors...
www.locatebio.com
@LocateBio will be attending the Biotech Showcase at #jpm2019 in San Francisco on 7-9 January 2019. Nick Staples, CEO and Professor Kevin Shakesheff, CSO will be available for meetings.
Gallery
